Expand HOTH Menu
HOTH MENU

HOTH Latest Press Releases

-- January 22, 2026 --

Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients PRNewswire 8:13 AM

-- January 21, 2026 --

Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position PRNewswire 8:13 AM

-- January 15, 2026 --

Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation PRNewswire 8:17 AM

-- January 2, 2026 --

Hoth Therapeutics Expands Oncology Pipeline with Dual Patent Filings Establishing Novel Oncology Dermatology IP Platform PRNewswire 8:13 AM

-- December 3, 2025 --

Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic Program PRNewswire 2:00 PM

-- December 1, 2025 --

Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 PRNewswire 8:03 AM

-- November 20, 2025 --

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities PRNewswire 8:13 AM

-- October 27, 2025 --

Hoth Therapeutics Launches VA-Backed Study of Novel GDNF Weight Loss Therapy Targeting Obesity and Fatty Liver Disease PRNewswire 7:49 AM

-- October 21, 2025 --

Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers PRNewswire 8:23 AM

-- October 8, 2025 --

Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform PRNewswire 8:02 AM

-- October 7, 2025 --

Hoth Therapeutics CEO Robb Knie to Present at BIO-Europe in Vienna, Austria November 3-5, 2025 PRNewswire 7:57 AM

-- September 24, 2025 --

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities PRNewswire 8:13 AM

-- September 22, 2025 --

Crypto and Cancer: How Biotech's New Strategy Is Turning Heads Yolowire 2:59 PM

-- September 16, 2025 --

Hoth Therapeutics Issues Shareholder Update: HT-001, HT-KIT, Expanded Treasury Reserve Strategy, and VA Obesity Program Drive Strongest Position in Company History PRNewswire 8:14 AM

-- September 10, 2025 --

Hoth Therapeutics Secures Key European Regulatory Milestone with EMA Submission for Phase II Trial of HT-001 in Cancer Patients Suffering from EGFRi-Induced Skin Toxicities PRNewswire 8:29 AM

-- September 4, 2025 --

Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development PRNewswire 8:16 AM

-- September 2, 2025 --

Hoth Therapeutics' Cancer Therapeutic HT-KIT Surpasses Preclinical Milestones With Potent Anti-Tumor Activity and GLP-Validated Bioanalytical Results, Exceeding Regulatory Standards PRNewswire 8:16 AM
EXCLUSIF : La thrapie antisens de Hoth Therapeutics dmontre son efficacit contre les cancers induits par KIT Vandana Singh 7:46 AM
EXKLUSIV: Die Antisense-Therapie von Hoth Therapeutics zeigt Wirksamkeit gegen KIT-getriebene Krebserkrankungen Vandana Singh 7:46 AM
ESCLUSIVO: La terapia antisenso di Hoth Therapeutics dimostra efficacia contro i tumori guidati da KIT Vandana Singh 7:46 AM
EXCLUSIVA: La terapia antisentido de Hoth Therapeutics demuestra eficacia contra los cnceres impulsados por KIT Vandana Singh 7:46 AM
EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers Vandana Singh 7:46 AM
Market Data Delayed 15 Minutes